Phase 2 N=121 Phase II ABT-888 With Cyclophosphamide
Ovarian Cancer · Primary Peritoneal Cancer · Serous Carcinoma Cancer
Primary: Percentage of Participants With an Overall Response Rate — 9.5; 5.6; 0; 11.8 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=13 Bacteriotherapy in Pediatric Inflammatory Bowel Disease
Inflammatory Bowel Disease · Crohn's Disease · Ulcerative Colitis
Primary: Number of Participants Who Responded to Stool Translplantation By 2 Weeks as Determined by Pediatric Ulcerative Colitis Activity Index (PUCAI)/Pediatric Crohn's Disease…
Phase 2 N=105 Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy
Cancer · Influenza Viral Infections
Primary: The Geometric Mean Titer (GMT) of High-dose Influenza Vaccine vs the Standard Trivalent Influenza Vaccine in Adult Subjects on Chemotherapy Who Are Less Than 65 Years…
N/A N=50 Effects of Paclitaxel on Intimal Hyperplasia
Peripheral Vascular Disease
Primary: Evidence of Stenosis Lower Extremity Post Revascularization Using Ankle-Brachial Index Measurement at 10 Months — 0.93 ratio
Phase 4 N=60 Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)
Cystic Fibrosis
Primary: Mean Total Administration Time — 37.0; 16.4; 4.2; 5.0 minutes
N/A N=127 Feasibility Study on the Model School Pediatric Health Initiative Pilot Project
School Board Health Centers
Primary: Number of Enrolled Participants Who Attended SBHC — 127; 252 participants
Phase 4 N=21 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy
Diabetic Nephropathy
Primary: the Change of Tissue Content of Deoxyhemoglobin Assessed by BOLD-MRI — 22.04 1/ms
Phase 3 N=452 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Squamous Cell Carcinoma
Primary: Overall Survival — 14.26; 17.51; 12.68; 16.20 months
Phase 2 N=8 Phase II Study, Evaluation of Safety and Efficacy of IdeS in Chronic Kidney Disease
Chronic Kidney Disease
Primary: Efficacy — 372 MFI
Phase 1 N=34 Drug-Drug Interaction Study Between TAK-272 and Itraconazole, Digoxin or Midazolam
Japanese Healthy Adult Males
Primary: Cmax: Maximum Observed Plasma Concentration for TAK 272F and TAK 272-Metabolite (M-I) in Cohort 1 — 387.8; 780.3; 10.02; 0.9550 nanogram per milliliter (ng/mL)
Phase 1 N=11 A Study to Compare Plasma Levels of Levodopa, Carbidopa and Entacapone After TRIGEL or Duodopa Infusion in PD Patients
Parkinson's Disease
Primary: Dose Adjusted Area Under the Curve (AUC) (0-14h) for Levodopa — 40.6; 29.4 h*ng/mL/mg — p=<0.0001
Phase 1 N=40 Assessment of Single Doses of Oral Dexanabinol in Healthy Subjects
Safety · Tolerability · Pharmacokinetics
Primary: Safety and Tolerability Based on the Number of Participants With Adverse Events and Comparison of Baseline and Post Dose Parameters — 9; 1 participants
Phase 4 N=92 Ranitidin Versus Omeprazole in Patients Taking Clopidogrel
Coronary Artery Disease · Drug Interaction Potentiation
Primary: Comparing Platelet Function of Patients on Dual Antiplatelet Therapy With ASA + Clopidogrel, Between the Groups Ranitidin and Omeprazole, After One Week of Randomized…
Phase 3 N=551 Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving an American College of Rheumatology Response 20 (ACR20). — 28.3; 30.7; 18.1; 42.8 Percentage of participants — p=0.0458
Phase 4 N=281 The Effect of Liposomal Lidocaine on Perceived Pain in Children During Percutaneous Interosseous Pin Removal in the Outpatient Setting
Pain
Primary: Pain — 0.70; 0.88; 1.04; 0.87 units on a scale